Please select the outcome measures that correspond to the clinical trial below.
Title: Direct Current Stimulation Versus Sham for Treatment of Fibromyalgia: a Double Blinded Randomized Controlled Trial
Brief Summary: The aim of this study is to assess the effectiveness of transcranial direct current stimulation (tDCS) in treating fibromyalgia.

Participants will be randomly assigned to one of the two groups: Group I (Intervention group) tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally Anodal tDCS for 20 minutes at 1.5 mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week) . The anodal electrode (24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).

Daily tDCS was given to prolong and stabilize these long-lasting after-effects. Group II will receive sham tDCS will be applied using the above described parameters in group I. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients. All study participants will be followed up by the same evaluation sheet and by an evaluator who are blinded to the type of intervention she /he has received.Evaluation will be done pre assessment, post 5 sessions, post 10 sessions, post one month and post 2 months by using wide spread pain index (WPI) \& symptoms severity of fibromyalgia, measuring visual analogue scale (VAS), Depression and anxiety will be assessed using Hamilton Depression Scale (HDS) and anxiety scale, pain sensitivity threshold by using Electronic Von Frey unit EVF4 . Determination of human beta-endorphin level before start sessions and after end 10 sessions.


Options:
A: Numeric Rating Scale (NRS) for Pain (baseline); Numeric Rating Scale (NRS) for Pain (day 5); Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale (baseline); Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale (day 5); Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Continuous Pain Subscale (baseline); Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Continuous Pain Subscale (day 5); Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Intermittent Pain Subscale (baseline); Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Intermittent Pain Subscale (day 5); Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Neuropathic Pain Subscale (baseline); Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Neuropathic Pain Subscale (day 5); Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Affective Pain Subscale (baseline); Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) Affective Pain Subscale (day 5); Six-minute Walk Test (baseline); Six-minute Walk Test (day 5); Short Physical Performance Battery (SPPB) (baseline); Short Physical Performance Battery (SPPB) (day 5); Heat Pain Threshold (baseline); Heat Pain Threshold (day 5); Heat Pain Tolerance (baseline); Heat Pain Tolerance (day 5); Pressure Pain Threshold (baseline); Pressure Pain Threshold (day 5); Punctate Mechanical Pain Sensitivity (baseline); Punctate Mechanical Pain Sensitivity (day 5); Conditioned Pain Modulation (CPM) (baseline); Conditioned Pain Modulation (CPM) (day 5)
B: Change in pain Scores as measured by the Visual Analog Scale (2 months)
C: Analgesic efficiency (36 months)
D: Pain severity (up to three months after the end of treatment)

Answer: B